On the 20th, Chordia Therapeutics announced that the CLK inhibitor CTX-712, which the company is developing, has been published by the World Health Organization (WHO) as the recommended International Nonproprietary Name (rINN). In the future, this development item will be listed under the INN name "rogocekib" instead of the development code CTX-712.
The INN is a unique name for pharmaceuticals that is standardized worldwide and is reviewed and designated by the WHO. Since there are multiple pharmaceuticals containing the same compound, assigning a single standard name to one substance is expected to facilitate communication related to pharmaceuticals. Therefore, the company's acquisition of an INN this time serves as evidence that activities toward commercialization have progressed.
Rogocekib is a first-in-class selective oral low molecular weight inhibitor of CDC2-like kinase (CLK), a key regulatory factor in the RNA splicing reaction which plays an important role in cell proliferation, and is currently undergoing Phase 1/2 clinical trials in the usa.
